Extra: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
*CD33 a useful marker contributing to the diagnosis of aml | |||
*less specific than myeloperoxidase and may be less sensitive than CD117 | |||
*there recognised aberrant expression by primitive lymphoid cells 10-20% | |||
*mature cells of myeloid lineage also express CD33 so gating essential | |||
</div> | </div> | ||
Line 18: | Line 17: | ||
<span style="color:navy">'''Normal expression and function'''</span> | <span style="color:navy">'''Normal expression and function'''</span> | ||
CD33 a transmembrane receptor that recognizes sialic acid-bearing glycans it thought that CD33 functions as an inhibitory protein u8e28093 supressing signals of the innate immune system. CD33 strongly expressed on multi-lineage hematopoietic progenitors and myelomonocytic precursors; but absent from the more primitive pluripotent hematopoietic stem cells. expression of CD33 down-regulated on mature granulocytes. CD33 also expressed on human mast cells and blood basophils. | |||
Line 24: | Line 24: | ||
<span style="color:navy">'''Diagnostic role'''</span> | <span style="color:navy">'''Diagnostic role'''</span> | ||
*overall around 80-90 of aml will express CD33; it tends not to be expressed in the most immature forms or those with erythroid or megakaryocytic differentiation | |||
* | *high CD33 expression may correlate with npm1 mutation | ||
* | *approximately 10% of b lymphoblastic or t lymphoblastic leukaemia lymphomas may aberrantly express CD33. | ||
* | *CD33 can also be aberrantly expressed on some cases of plasma cell myeloma up to 25% | ||
CD33 not expressed by mature erythrocytes platelets b-cells t-cells or nk cells. | |||
however CD33 expressed throughout myeloid maturation and so found on mature myeloid cells | |||
Line 35: | Line 36: | ||
<span style="color:navy">'''Other relevant information:'''</span> | <span style="color:navy">'''Other relevant information:'''</span> | ||
CD33 has received particular attention as the molecular target of antibody-based treatment strategies in the therapy of aml. gemtuzumab ozogamicin go; mylotarg consists of a recombinant humanized anti-CD33 antibody conjugated to a derivative of the cytotoxic antitumor agent calicheamicin. | |||
Line 87: | Line 88: | ||
<span style="font-size:90%">'''Notes:''' *Expression is not always seen in MCL but may have high intensity **Strong expression intensity is expected in HCL</span> | <span style="font-size:90%">'''Notes:''' *Expression is not always seen in MCL but may have high intensity **Strong expression intensity is expected in HCL</span> | ||
summary tables | |||
expression by acute leukaemias and by haematogones | |||
poss pro-b all | |||
poss early pre-b all | |||
poss pre-b all | |||
poss b all | |||
poss pro-t all | |||
poss mature-t all | |||
hi aml | |||
freq haemato-gones | |||
notes *in all the expression of CD33 more likely in b-lineage but also seen in t-all | |||
**in aml CD33 expressed in around 80 of cases ***in haematogones expression of CD33 frequent | |||
expression by b-lymphoproliferative disorders | |||
rare cll | |||
rare pll | |||
rare mcl | |||
rare fl' | |||
rare hcl | |||
rare hclv | |||
rare mzl | |||
rare lpl | |||
poss pcs | |||
*CD33 occasionally expressed in mature lymphoid malignancies more frequently in b cell types | |||
{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;" | {| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;" |
Revision as of 17:02, 15 May 2023
- Summary
- CD33 a useful marker contributing to the diagnosis of aml
- less specific than myeloperoxidase and may be less sensitive than CD117
- there recognised aberrant expression by primitive lymphoid cells 10-20%
- mature cells of myeloid lineage also express CD33 so gating essential
Normal expression and function
CD33 a transmembrane receptor that recognizes sialic acid-bearing glycans it thought that CD33 functions as an inhibitory protein u8e28093 supressing signals of the innate immune system. CD33 strongly expressed on multi-lineage hematopoietic progenitors and myelomonocytic precursors; but absent from the more primitive pluripotent hematopoietic stem cells. expression of CD33 down-regulated on mature granulocytes. CD33 also expressed on human mast cells and blood basophils.
Diagnostic role
- overall around 80-90 of aml will express CD33; it tends not to be expressed in the most immature forms or those with erythroid or megakaryocytic differentiation
- high CD33 expression may correlate with npm1 mutation
- approximately 10% of b lymphoblastic or t lymphoblastic leukaemia lymphomas may aberrantly express CD33.
- CD33 can also be aberrantly expressed on some cases of plasma cell myeloma up to 25%
CD33 not expressed by mature erythrocytes platelets b-cells t-cells or nk cells. however CD33 expressed throughout myeloid maturation and so found on mature myeloid cells
Other relevant information:
CD33 has received particular attention as the molecular target of antibody-based treatment strategies in the therapy of aml. gemtuzumab ozogamicin go; mylotarg consists of a recombinant humanized anti-CD33 antibody conjugated to a derivative of the cytotoxic antitumor agent calicheamicin.
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
Expression in primitive cell types | |||||||
---|---|---|---|---|---|---|---|
AML | CMML | B ALL | Burkitt | T ALL | ETP ALL <I> | MPAL <I> | Hgns <I> |
5-20% | <5% | 5-20% | <5% | <5% | <5% | <5% | <5% |
Notes: Expression in B-ALL may be associated with BCR::ABL1 expression
Expression in mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
20-40% | 20-40%* | 5-20% | 20-40% | 80-100%** | 5-20% | 40-80% | <5% |
Notes: *Expression is not always seen in MCL but may have high intensity **Strong expression intensity is expected in HCL
summary tables expression by acute leukaemias and by haematogones poss pro-b all poss early pre-b all poss pre-b all poss b all poss pro-t all poss mature-t all hi aml freq haemato-gones notes *in all the expression of CD33 more likely in b-lineage but also seen in t-all
- in aml CD33 expressed in around 80 of cases ***in haematogones expression of CD33 frequent
expression by b-lymphoproliferative disorders rare cll rare pll rare mcl rare fl' rare hcl rare hclv rare mzl rare lpl poss pcs
- CD33 occasionally expressed in mature lymphoid malignancies more frequently in b cell types
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
80-100%* | 40-80% | 5-20% | <5% | <5% |
Notes: CD25 has characteristically strong expression on ATLL, but other T-LPD also express the marker less strongly